Liu Yawen, Chen Chunlong, Liao Binfan, Geng Xiuzhu, Huang Weijin, Nie Jianhui
Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.
The Sixth Laboratory, National Vaccine & Serum Institute (NVSI), Beijing, People's Republic of China.
Emerg Microbes Infect. 2025 Dec;14(1):2555721. doi: 10.1080/22221751.2025.2555721. Epub 2025 Sep 16.
The New World alphaviruses, including Eastern Equine Encephalitis Virus (EEEV), Western Equine Encephalitis Virus (WEEV), and Venezuelan Equine Encephalitis Virus (VEEV), are known to cause neurological diseases that pose a significant threat to public health concerns and bioterrorism preparedness challenges due to their potential for aerosol transmission. Currently, no FDA-approved vaccines or antiviral drugs are available for humans, although ongoing studies are exploring potential solutions. Most vaccine evaluation methods rely on live virus models, which require handling in biosafety level 3 (BSL-3) facilities. In this study, we constructed pseudoviruses for NW alphaviruses using the vesicular stomatitis virus (VSV) system by expressing the glycoproteins E3-E2-E1 on the surface of the VSV vector. cell infection experiments revealed that the pseudovirus titres of EEEV and VEEV were comparatively higher. Bioluminescence imaging in a mouse model was used to assess infection . When injected into the brain, this was the main site of infection for NW alphavirus-based pseudoviruses. When administered via the tail vein, the pseudovirus primarily infected the spleen, while intraperitoneally injected pseudoviruses mainly infected the intestines and thymus. Furthermore, we systematically evaluated the correlation between neutralizing antibody titres induced by DNA immunization and the protection against homologous virus strains. This study establishes a safe, convenient, and efficient system for evaluating the protective effects of vaccines against NW alphaviruses, which can be operated in a BSL-2 facility.
包括东部马脑炎病毒(EEEV)、西部马脑炎病毒(WEEV)和委内瑞拉马脑炎病毒(VEEV)在内的新大陆甲病毒,已知会引发神经系统疾病,因其具有气溶胶传播的可能性,对公共卫生问题和生物恐怖主义防范挑战构成重大威胁。目前,尚无FDA批准的用于人类的疫苗或抗病毒药物,不过正在进行的研究正在探索潜在的解决方案。大多数疫苗评估方法依赖于活病毒模型,这需要在生物安全3级(BSL - 3)设施中进行操作。在本研究中,我们利用水泡性口炎病毒(VSV)系统构建了新大陆甲病毒的假病毒,通过在VSV载体表面表达糖蛋白E3 - E2 - E1。细胞感染实验表明,EEEV和VEEV的假病毒滴度相对较高。在小鼠模型中利用生物发光成像来评估感染情况。当注入大脑时,这是基于新大陆甲病毒的假病毒的主要感染部位。当通过尾静脉给药时,假病毒主要感染脾脏,而腹腔注射的假病毒主要感染肠道和胸腺。此外,我们系统地评估了DNA免疫诱导的中和抗体滴度与针对同源病毒株的保护作用之间的相关性。本研究建立了一个安全、便捷且高效的系统,用于评估疫苗对新大陆甲病毒的保护效果,该系统可在BSL - 2设施中操作。